Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer.

@article{Tian2015ProductionAC,
  title={Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer.},
  author={Baomin Tian and Wah Yau Wong and Elda Hegmann and K. J. Gaspar and Praveen Kumar and Heman Chao},
  journal={Bioconjugate chemistry},
  year={2015},
  volume={26 6},
  pages={
          1144-55
        }
}
A novel immunoconjugate (L-DOS47) was developed and characterized as a therapeutic agent for tumors expressing CEACAM6. The single domain antibody AFAIKL2, which targets CEACAM6, was expressed in the Escherichia coli BL21 (DE3) pT7-7 system. High purity urease (HPU) was extracted and purified from Jack bean meal. AFAIKL2 was activated using N-succinimidyl [4-iodoacetyl] aminobenzoate (SIAB) as the cross-linker and then conjugated to urease. The activation and conjugation reactions were… 
Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2
TLDR
V21-DOS47 is an immunoconjugate that targets VEGFR2 and can be efficiently generated and purified using methods easily transferrable for cGMP production, and is determined to be the superior conjugate as the antibody is easily produced and purified at high levels.
Convenient and Universal Fabrication Method for Antibody-Enzyme Complexes as Sensing Elements Using the SpyCatcher/SpyTag System.
TLDR
This method results in the convenient and universal preparation of sensing elements with the potential for electrochemical measurement and confirmed the universality of this AEC fabricating method by applying it to another VHH.
Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect
TLDR
This study clearly demonstrated that the anti-EGFR sdAbs could inhibit cancer cell growth in vitro and tumor growth in vivo.
Anticancer Activity of Urease Mimetic Cobalt (III) Complexes on A549-Lung Cancer Cells: Targeting the Acidic Microenvironment
TLDR
The study confirms the urease mimicking anticancer activity of cobalt (III) complexes by neutralizing the tumour microenvironment.
Fabrication of Fragment Antibody–Enzyme Complex as a Sensing Element for Immunosensing
TLDR
The methods for fabricating AECs using fragment antibodies developed for sensing applications are summarized and the advantages and disadvantages of each method are discussed.
Improving the targeting of therapeutics with single-domain antibodies
TLDR
This work has shown that the identification of novel protein modification techniques will provide more options for sdAb modification (conjugation, immobilization, functionalization), allowing a wider array of therapeutic agents to be successfully targeted and delivered using sdAbs.
Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases
TLDR
The characteristic properties of single-domain antibodies compared to traditional antibodies are introduced and recent advances in the development of sdAbs are presented, including their use for the delivery of biologics across the blood–brain and blood–cerebrospinal fluid barriers, treatment of neurodegenerative diseases and molecular imaging of brain targets.
Theranostics in immuno-oncology using nanobody derivatives
TLDR
This review provides a comprehensive overview on the state-of-the-art regarding the use of nanobodies as theranostics, and their importance in the emerging field of personalized medicine.
Acidosis and cancer: from mechanism to neutralization
TLDR
This review will revisit the causes and consequences of acidosis by summarizing strategies used by cancer cells to adapt to acidosis, and how neutralization of acidity can be used to inhibit carcinogenesis and metastasis and improve anti-cancer immunotherapy.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
  • M. Napier, S. Sharma, R. Begent
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
Ten patients with colorectal carcinoma expressing carcinoembryonic antigen received antibody-directed enzyme prodrug therapy with A5B7 F(ab')2 antibody to carcino embryo antigen conjugated to carboxypeptidase G2 (CPG2), and conditions for effective antitumor therapy were met.
Antibody-Directed Enzyme Prodrug Therapy
TLDR
In experimental systems, immunospecific antitumour effects have been demonstrated with ADEPT, much greater than can be achieved by systemic administration of either the prodrug or active drug alone.
Antibody directed enzymes revive anti-cancer prodrugs concept.
TLDR
Within a few years of the beginnings of cancer chemotherapy anticancer prodrugs were being synthesised, one of the compounds produced at the Chester Beatty had a profound effect on growth of the Walker rat carcinoma, both in vivo and in culture, whilst it had little or no effect on other cancers.
Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers.
TLDR
Alkalinization of extracellular pH by urease and urea was found to enhance the antitumor efficacy of doxorubicin and vinblastine significantly and when combined with weak-base anticancer drugs, Urease provided indirect antitumors effects via pH augmentation.
Antibody repertoire development in camelids.
Targeted drug delivery for cancer therapy: the other side of antibodies
TLDR
A review of TMAs and ADCs approved for clinical use by the FDA and those in development and the advantages and disadvantages of naked TMAs, ADCs and PDCs is presented to develop a more rational approach to the application of targeted drug delivery strategies in different situations.
Single‐domain antibody fragments with high conformational stability
TLDR
All the fragments are rather resistant to heat‐induced denaturation, and display high conformational stabilities, which has never been reported for any functional conventional antibody fragment, even when engineered antigen binders are considered.
...
...